Legato Capital Management LLC Has $1.11 Million Stock Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Legato Capital Management LLC decreased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 23.5% during the 4th quarter, Holdings Channel reports. The fund owned 184,668 shares of the company’s stock after selling 56,690 shares during the quarter. Legato Capital Management LLC’s holdings in Adaptive Biotechnologies were worth $1,107,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ADPT. China Universal Asset Management Co. Ltd. boosted its position in shares of Adaptive Biotechnologies by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company’s stock worth $188,000 after purchasing an additional 2,928 shares in the last quarter. KBC Group NV acquired a new stake in Adaptive Biotechnologies during the 4th quarter worth $50,000. Impact Partnership Wealth LLC lifted its holdings in Adaptive Biotechnologies by 8.8% during the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,539 shares in the last quarter. SG Americas Securities LLC grew its stake in Adaptive Biotechnologies by 11.7% in the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company’s stock valued at $275,000 after acquiring an additional 4,799 shares during the period. Finally, GAMMA Investing LLC bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth about $59,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ADPT shares. The Goldman Sachs Group lifted their price objective on Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Piper Sandler upped their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Finally, BTIG Research increased their price objective on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $7.55 on Thursday. The business has a 50-day moving average of $6.92 and a 200-day moving average of $5.59. Adaptive Biotechnologies Co. has a fifty-two week low of $2.28 and a fifty-two week high of $8.33. The stock has a market capitalization of $1.11 billion, a P/E ratio of -5.63 and a beta of 1.50.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 62.06% and a negative net margin of 110.13%. During the same quarter in the prior year, the company posted ($0.30) earnings per share. Equities analysts expect that Adaptive Biotechnologies Co. will post -1.08 EPS for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.